Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Declines By 97.9%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totalling 150,000 shares, a drop of 97.9% from the December 15th total of 7,300,000 shares. Based on an average daily volume of 906,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 16.5% of the shares of the stock are sold short.

CERo Therapeutics Price Performance

NASDAQ:CERO traded down $0.22 on Wednesday, hitting $2.58. The company had a trading volume of 333,613 shares, compared to its average volume of 1,553,872. The firm has a 50 day moving average of $11.62 and a two-hundred day moving average of $12.81. CERo Therapeutics has a 52 week low of $2.51 and a 52 week high of $1,280.00.

Insider Buying and Selling at CERo Therapeutics

In other news, major shareholder Bioventures Opportunities G. Yk sold 12,368 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.00, for a total value of $148,416.00. Following the sale, the insider now directly owns 213,839 shares in the company, valued at approximately $2,566,068. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 64,300 shares of company stock valued at $529,409. 18.00% of the stock is currently owned by corporate insiders.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.